Pazopanib Hydrochloride CAS 635702-64-6 Maʻemaʻe >99.0% (HPLC) API Hale Hana

ʻO ka wehewehe pōkole:

Inoa Kemika: Pazopanib Hydrochloride

CAS: 635702-64-6

Ke 'ano: Ke'oke'o i ka pauda melemele iki

Maʻemaʻe: >99.0% (HPLC)

ʻO Tyrosine kinase receptor inhibitor no ka mālama ʻana i ka maʻi maʻi maʻi renal cell carcinoma a i ʻole sarcoma maʻi palupalu kiʻekiʻe

API Kūlana Kiʻekiʻe, Hana Hana Kūʻai

Inquiry: alvin@ruifuchem.com


Huahana Huahana

Nā Huahana Pili

Huahana Huahana

wehewehe:

Hāʻawi Mea Hana me ka Maʻemaʻe kiʻekiʻe a me ka maikaʻi paʻa
Inoa Kemika: Pazopanib Hydrochloride
CAS: 635702-64-6
ʻO Tyrosine kinase receptor inhibitor no ka mālama ʻana i ka maʻi maʻi maʻi renal cell carcinoma a i ʻole sarcoma ʻili palupalu kiʻekiʻe i loaʻa mua i ka chemotherapy.
API Kūlana Kiʻekiʻe, Hana Hana Kūʻai

Na Waiwai Kemika:

Inoa Kimia ʻO ka Pazopanib Hydrochloride
Nā huaʻōlelo like Pazopanib HCl;GW786034 HCl;Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
Helu CAS 635702-64-6
Helu CAT RF-API93
Kūlana Kūʻai Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram
ʻĀpana Molekala C21H23N7O2S.ClH
Kaumaha Molecular 473.987
Ka hikiwawe DMSO
Lae hehee 300.0~304.0 ℃
Brand Kemika Ruifu

Nā kikoʻī:

'ikamu Nā kikoʻī
Ka nana aku Pauda keokeo a melemele iki
ʻIkepili ʻO ke ʻano o ka infraed absorption spectrum o ka laʻana hoʻāʻo e kūlike me ka maʻamau
Koena ma ka Ignition ≤0.50%
ʻO kēlā me kēia haumia kanaka ≤0.30%
Huina paumaele ≤1.50%
Nā Metala Kaumaha ≤10ppm
Maʻemaʻe / Kaʻina Hanana ≥99.0% (HPLC)
Kūlana hoʻāʻo Kūlana ʻoihana
Hoʻohana API, Tyrosine kinase receptor inhibitor

Pūʻolo a me ka waiho ʻana:

Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.

Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.

Pono:

1

FAQ:

Noi:

Pazopanib Hydrochloride (CAS 635702-64-6) he multi-tyrosine kinase inhibitor o vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR) -α a me - β, fibroblast growth factor receptor (FGFR) -1 a me -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), a me ka transmembrane glycoprotein receptor tyrosine kinase (cFms).In vitro, pazopanib inhibited ligand-induced autophosphorylation o VEGFR-2, Kit, a me PDGFR-beta receptors.In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation i loko o nā māmāʻiole, angiogenesis i loko o kaʻiole kŘkohu, a me ka ulu ana o kekahi mau xenografts tumo kanaka ma ka iole.Ua ʻae ʻia ia no ka maʻi maʻi maʻi renal cell e ka US Food and Drug Administration ma 2009 a kūʻai ʻia ma lalo o ka inoa kālepa Votrient e ka mea hana lāʻau, ʻo GlaxoSmithKline.ʻO ka Votrient he mea hoʻopaneʻe kinase i hōʻike ʻia no ka mālama ʻana i nā poʻe maʻi me: 1) ka maʻi maʻi maʻi renal cell carcinoma.2) ka maʻi maʻi maʻi maʻemaʻe i loaʻa mua i ka chemotherapy.

E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou